Innovent Advances Two ADC Programs After ESMO Presentations

Overview

• Innovent presented multicenter Phase 1 results for IBI3001, a bispecific EGFR/B7H3 antibody–drug conjugate that showed a manageable safety profile with no treatment‑related deaths and Grade ≥3 treatment‑related adverse events in 47.4% of patients.
• Among 53 efficacy‑evaluable patients, IBI3001 produced an overall objective response rate of 30.2% and disease control rate of 88.7%, with higher responses (ORR 45.0%) in the 8 mg/kg cohort and tumor‑specific signals in EGFR‑mutant NSCLC, pancreatic cancer, and small‑cell lung cancer.
• IBI3001 has moved into a Phase 1b dose‑optimization proof‑of‑concept stage to refine dosing and expand evaluation in later‑line refractory solid tumors.
• Innovent also reported Phase 2 first‑line data for IBI354, a HER2 ADC given with pertuzumab, showing a confirmed response rate of 95%, 100% disease control in 20 patients, and a favorable safety profile with no interstitial lung disease reported.
• Together these updates show Innovent shifting its ADC platform from early proof‑of‑concept to registrational development, which could speed testing of these drugs in larger trials and potentially expand treatment options for patients with hard‑to‑treat solid tumors.